Oncogene-Driven Hemostatic Changes in Cancer

REFERENCES

• Buller H. R., van Doormaal F. F., van Sluis G. L., Kamphuisen P. W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5(Suppl. 1)246–254
   PubMedGoogle Scholar
• Zwicker J. I., Furie B. C., Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62: 126–136
   PubMed Web of Science ®Google Scholar
• Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31: 104–110
   PubMed Web of Science ®Google Scholar
• Rickles F. R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006; 35: 103–110
   PubMed Web of Science ®Google Scholar
• Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel -Dieu de Paris. The Sydenham Society 2nd. 1865; 654–712, Paris, France. Ref Type: Serial (Book, Monograph)
   Google Scholar
• Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723–1729
   PubMed Web of Science ®Google Scholar
• Tesselaar M. E., Romijn F. P., van dL I., et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5: 520–527
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936
   PubMed Web of Science ®Google Scholar
• Jain R. K., di T. E., Duda D. G., et al. Angiogenesis in brain tumors. Nat Rev Neurosci 2007; 8: 610–622
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Patierno S., Fernandez P. M. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S–68S
   PubMed Web of Science ®Google Scholar
• Petralia G. A., Lemoine N. R., Kakkar A. K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005; 2: 356–363
   PubMedGoogle Scholar
• Rak J., Yu J. L., Luyendyk J., Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643–10646
   PubMed Web of Science ®Google Scholar
• Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722
   PubMed Web of Science ®Google Scholar
• Svendsen E., Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989; 42: 805–809
   PubMed Web of Science ®Google Scholar
• Levitan N., Dowlati A., Remick S. C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
   PubMed Web of Science ®Google Scholar
• Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005; 25: 2273–2281
   PubMed Web of Science ®Google Scholar
• Iversen L. H., Thorlacius-Ussing O. Systemic coagulation reactivation in recurrence of colorectal cancer. Thromb Haemost 2003; 89: 726–734
   PubMed Web of Science ®Google Scholar
• Kuenen B. C., Rosen L., Smit E. F., et al. Dose-finding and pharmacokinetic study of cisplatin, gGemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657–1667
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Levine M. N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28(Suppl. 3)43–49
   PubMedGoogle Scholar
• Reya T., Morrison S. J., Clarke M. F., Weissman I. L. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111
   PubMed Web of Science ®Google Scholar
• Folkman J., Kalluri R. Tumor angiogenesis. Cancer Medicine, D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, et al. BC Decker Inc., Hamilton, London 2003; 161–194
   Google Scholar
• Brown L. F., Guidi A. J., Schnitt S. J., et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041–1056
   PubMed Web of Science ®Google Scholar
• Kaplan R. N., Riba R. D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820–827
   PubMed Web of Science ®Google Scholar
• Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Bishop J. M. Cancer: the rise of the genetic paradigm. Genes Dev 1995; 9: 1309–1315
   PubMed Web of Science ®Google Scholar
• Rak J., Yu J. L., Klement G., Kerbel R. S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000; 5: 24–33
   PubMed Web of Science ®Google Scholar
• Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575–4580
   PubMed Web of Science ®Google Scholar
• Kerbel R. S. Tumor angiogenesis. N Engl J Med 2008; 358: 2039–2049
   PubMed Web of Science ®Google Scholar
• Ocak I., Baluk P., Barrett T., McDonald D. M., Choyke P. The biologic basis of in vivo angiogenesis imaging. Front Biosci 2007; 12: 3601–3616
   PubMed Web of Science ®Google Scholar
• Seaman S., Stevens J., Yang M. Y., et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539–554
   PubMed Web of Science ®Google Scholar
• Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–4380
   PubMed Web of Science ®Google Scholar
• Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015–1022
   PubMed Web of Science ®Google Scholar
• Mechtcheriakova D., Schabbauer G., Lucerna M., et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230–242
   PubMed Web of Science ®Google Scholar
• Contrino J., Hair G., Kreutzer D. L., Rickles F. R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209–215
   PubMed Web of Science ®Google Scholar
• Fidler I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458
   PubMed Web of Science ®Google Scholar
• Dvorak H. F., Quay S. C., Orenstein N. S., et al. Tumor shedding and coagulation. Science 1981; 212: 923–924
   PubMed Web of Science ®Google Scholar
• Yu J. L., May L., Lhotak V., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734–1741
   PubMed Web of Science ®Google Scholar
• Rak J., Milsom C., Yu J. Tissue factor in cancer. Curr Opin Hematol 2008; 15: 522–528
   PubMed Web of Science ®Google Scholar
• Rak J., Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000; 19: 93–96
   PubMed Web of Science ®Google Scholar
• Rastinejad F., Polverini P. J., Bouck N. Regulation of the activity of a new inhibitor by angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345–355
   PubMed Web of Science ®Google Scholar
• Dameron K. M., Volpert O. V., Tainsky M. A., Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994; 59: 483–489
   PubMedGoogle Scholar
• Bouck N., Stellmach V., Hsu S. C. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135–174
   PubMed Web of Science ®Google Scholar
• Grugel S., Finkenzeller G., Weindel K., Barleon B., Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995; 270: 25915–25919
   PubMed Web of Science ®Google Scholar
• Izumi H., Takahashi C., Oh J., Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 2000; 481: 31–36
   PubMed Web of Science ®Google Scholar
• Mazzieri R., Furlan F., D'Alessio S., et al. A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. Oncogene 2007; 26: 725–732
   PubMed Web of Science ®Google Scholar
• Zhao Y., Xiao A., Dipierro C. G., et al. H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia 2008; 56: 917–924
   PubMed Web of Science ®Google Scholar
• Pakneshan P., Szyf M., Rabbani S. A. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2005; 26: 557–564
   PubMed Web of Science ®Google Scholar
• Scibetta A. G., Albanese I., Morris J., et al. Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways. DNA Cell Biol 2001; 20: 265–274
   PubMed Web of Science ®Google Scholar
• Jahner D., Hunter T. The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes. Oncogene 1991; 6: 1259–1268
   PubMed Web of Science ®Google Scholar
• Yu J. L., May L., Klement P., Weitz J. I., Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004; 30: 21–30
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K., Meehan B., Micallef J., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. Nat Cell Biol 2008; 10: 619–624
   PubMed Web of Science ®Google Scholar
• Koizume S., Jin M. S., Miyagi E., et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66: 9453–9460
   PubMed Web of Science ®Google Scholar
• Schulze E. B., Hedley B. D., Goodale D., et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008; 112: 243–254
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Lefebvre P., Baine R. M., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2: 1341–1350
   PubMed Web of Science ®Google Scholar
• Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434: 396–400
   PubMed Web of Science ®Google Scholar
• Rong Y., Post D. E., Pieper R. O., et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406–1413
   PubMed Web of Science ®Google Scholar
• Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression?. J Thromb Haemost 2007; 5: 1584–1587
   PubMed Web of Science ®Google Scholar
• Pineo G. F., Brain M. C., Gallus A. S., et al. Tumors, mucus production, and hypercoagulability. Ann NY Acad Sci 1974; 230: 262–270
   PubMed Web of Science ®Google Scholar
• Mackman N., Morrissey J. H., Fowler B., Edgington T. S. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989; 28: 1755–1762
   PubMed Web of Science ®Google Scholar
• Chen J., Bierhaus A., Schiekofer S., et al. Tissue factor–a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 334–345
   PubMed Web of Science ®Google Scholar
• Fernandez P. M., Rickles F. R. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002; 9: 401–406
   PubMed Web of Science ®Google Scholar
• Morrissey J. H. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66–74
   PubMed Web of Science ®Google Scholar
• Giesen P. L., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311–2315
   PubMed Web of Science ®Google Scholar
• Colman R. W., Marder V. J., Salzman E. W., Hirsh J. Overview of hemostasis. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, R. B. Coleman, J. Hirsh, V. J. Marder, J. B. Salzman. Lippincott Company, Philadelphia 1994; 3–18
   Google Scholar
• Coughlin S. R. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298–307
   PubMed Web of Science ®Google Scholar
• Degen J. L. Genetic interactions between the coagulation and fibrinolytic systems. Thromb Haemost 2001; 86: 130–137
   PubMed Web of Science ®Google Scholar
• Shoji M., Abe K., Nawroth P. P., Rickles F. R. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997; 7(2)52–59
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz M. Z., Sierko E., Klement P., Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371–384
   PubMed Web of Science ®Google Scholar
• Ueno T., Toi M., Koike M., Nakamura S., Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164–170
   PubMed Web of Science ®Google Scholar
• Sawada M., Miyake S., Ohdama S., et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999; 79: 472–477
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Lemoine N. R., Scully M. F., Tebbutt S., Williamson R. C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101–1104
   PubMed Web of Science ®Google Scholar
• Koomagi R., Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79: 19–22
   PubMed Web of Science ®Google Scholar
• Seto S., Onodera H., Kaido T., et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88: 295–301
   PubMed Web of Science ®Google Scholar
• Shigemori C., Wada H., Matsumoto K., et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998; 80: 894–898
   PubMed Web of Science ®Google Scholar
• Nakasaki T., Wada H., Shigemori C., et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247–254
   PubMed Web of Science ®Google Scholar
• Denko N. C., Giaccia A. J. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001; 61: 795–798
   PubMed Web of Science ®Google Scholar
• Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505–516
   PubMed Web of Science ®Google Scholar
• Rak J., Milsom C., May L., Klement P., Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32: 54–70
   PubMed Web of Science ®Google Scholar
• Milsom C., Yu J., May L., et al. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb Res 2007; 120(Suppl. 2)S82–S91
   PubMedGoogle Scholar
• Yu J. L., Rak J. W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065–2067
   PubMed Web of Science ®Google Scholar
• Del I. C., Shrimpton C. N., Thiagarajan P., Lopez J. A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604–1611
   PubMed Web of Science ®Google Scholar
• Sanderson M. P., Keller S., Alonso A., et al. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 2008; 103: 1783–1797
   PubMed Web of Science ®Google Scholar
• Guan M., Jin J., Su B., Liu W. W., Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002; 35: 321–325
   PubMed Web of Science ®Google Scholar
• Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445–1453
   PubMed Web of Science ®Google Scholar
• Brat D. J., Van Meir E. G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004; 84: 397–405
   PubMed Web of Science ®Google Scholar
• Furnari F. B., Fenton T., Bachoo R. M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683–2710
   PubMed Web of Science ®Google Scholar
• Mellinghoff I. K., Wang M. Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012–2024
   PubMed Web of Science ®Google Scholar
• Pandolfi P. P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 2001; 10: 769–775
   PubMed Web of Science ®Google Scholar
• Milsom C., Anderson G. M., Weitz J. I., Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007; 5: 2550–2552
   PubMed Web of Science ®Google Scholar
• Belting M., Ahamed J., Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545–1550
   PubMed Web of Science ®Google Scholar
• Zacharski L. R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost 2003; 29: 239–246
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Rickles F. R., Julian J. A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–2129
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948
   PubMed Web of Science ®Google Scholar
• Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266–1271
   PubMed Web of Science ®Google Scholar
• Versteeg H. H., Schaffner F., Kerver M., et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190–199
   PubMed Web of Science ®Google Scholar
• Hu Z., Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostate cancer. Proc Natl Acad Sci USA 2002; 99: 6269–6273
   PubMedGoogle Scholar
• Milsom C. C., Yu J. L., Mackman N., Micallef J., Anderson G. M., Guha A., Rak J. Tissue factor regulation by epithelial growth factor receptor and epithelial-to-mesenchymal transitions: Effect on tumor initiation and angiogenesis. Cancer Res. 2008; 68: 10068–10076
   PubMed Web of Science ®Google Scholar
• Yu J., May L., Milsom C. C., Anderson G. M., Weitz J. I., Luyendyk J. P., Broze G., Mackman N., Rak J. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol, 2008; 28: 1975–1981
   PubMed Web of Science ®Google Scholar